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The Current Practice of Transarterial
Chemoembolization for the Treatment of
Hepatocellular Carcinoma
Despite remarkable advancement in the surveillance and treatment of hepato-
cellular carcinoma (HCC) and the availability of novel curative options, a great
proportion of HCC patients are still not eligible for curative treatment due to an
advanced tumor stage or poor hepatic functional reserve. Therefore, there is a
continuing need for effective palliative treatments. Although practiced widely, it
has only recently been demonstrated that the use of transarterial chemoem-
bolization (TACE) provides a survival benefit based on randomized controlled
studies. Hence, TACE has become standard treatment in selected patients.
TACE combines the effect of targeted chemotherapy with the effect of ischemic
necrosis induced by arterial embolization. Most of the TACE procedures have
been based on iodized oil utilizing the microembolic and drug-carrying character-
istic of iodized oil. Recently, there have been efforts to improve the delivery of
chemotherapeutic agents to a tumor. In this review, the basic principles, technical
issues and complications of TACE are reviewed and recent advancement in
TACE technique and clinical applicability are briefed. 
he liver has a unique dual blood supply from both the portal vein and the
hepatic artery. The normal parenchyma of the liver receives two-thirds of
its necessary blood supply from the portal vein and receives the remain-
ing one-third from the hepatic artery. However, it is well-known that vascularization
of hepatocellular carcinoma (HCC) is mostly dependent on the hepatic artery (1, 2).
This characteristic of HCC not only justifies the diagnostic use of contrast enhanced
CT and MRI, but also provides a basic rationale for transarterial therapy as an
effective treatment of HCC (3).
Though a variety of techniques and agents have been used to treat HCC with
transarterial therapy (4), transarterial chemoembolization (TACE) and transarterial
embolization (TAE) are the most widely accepted transarterial techniques to treat
HCC. TACE is a combination therapy of TAE and regional chemotherapy. Selective
arterial obstruction induces ischemic tumor necrosis while minimizing damage to the
liver tissue. The blood supply to the liver tissue is still maintained by dominant blood
flow from the portal vein minimizing damage to the liver. In addition, chemotherapeu-
tic agents concomitantly administered remain in a tumor for a longer period at a
higher concentration. The embolotherapy interrupts the arterial blood flow to a tumor
and prevents washout of the injected chemotherapeutic agents from a tumor.
Therefore, this combination of embolotherapy and regional chemotherapy has
synergistic, anti-tumor effects with a high objective response rate (Fig. 1). Another
added benefit is that the use of combination therapy results in lower systemic drug
levels and therefore less toxicity.
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TBasic Principles of Transarterial Chemoembolization
The selection of the most appropriate treatment option
for HCC patients depends not only on tumor burden but
also on liver function and the general performance status
of the patient. TACE is usually done in a selected group of
patients with multinodular HCCs who cannot benefit from
curative treatment (5). TACE is not done for patients with
a severely compromised liver function such as Child-Pugh
classification C or late B. Though superselective TACE
may be attempted in a patient with compromised liver
function, if the patient has a diffuse or massive HCC or an
HCC involving the major portal veins, this precludes the
practice of safe TACE. Therefore, residual liver function
should be evaluated through the use of laboratory tests
and clinical examinations, and the extent and characteris-
tics of a tumor need to be evaluated through the use of
imaging studies when TACE is planned.
As correct anatomical evaluation is essential to perform
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Fig. 1. 66-year-old man with hepatocellular carcinoma.
A, B. Early (A) and delayed (B) phases of contrast enhanced CT scans show large mass (arrowheads) in right hepatic lobe. Note filling
defect in inferior vena cava (arrow) that is tumor thrombus extending from right hepatic vein. 
C. Hepatic arteriogram shows infiltrative tumor staining in right hepatic lobe with formation of extensive arteriovenous shunt
(arrowheads). Transarterial chemoembolization was performed with mixture of 15 ml of Lipiodol and 50 mg of doxorubicin followed by
gelfoam embolization. This patient underwent four sessions of transarterial chemoembolization over period of five months.
D. Five months later, follow-up angiogram shows almost complete disappearance of tumor vascularity and only trace of arteriovenous
shunt is noted (arrowheads).
CDsegmental or subsegmental TACE, CT or MRI examina-
tions should be done prior to TACE. A thorough
angiographic examination is mandatory to locate all of the
feeding arteries of a tumor including any possible extra-
hepatic arteries that may feed the tumor. The possibility of
whether or not tumors will be supplied by extrahepatic
arteries can be predicted from CT or MRI findings. These
findings include the presence of a large tumor located at
the surface or a bare area, a peripheral area of a tumor
with no Lipiodol retention and visualization of hypertro-
phied extrahepatic arteries (6, 7).
Though TACE implementation is tailored according to
the liver function of each patient as well as the extent of
the tumor and portal vein involvement, the use selective
TACE more often can result in a better outcome with less
adverse effects. There is increasing evidence that selective
TACE achieves better antitumoral effects and reduces both
the dosage of drugs used for TACE and the number of
TACE sessions needed to achieve extensive tumor necrosis
as compared to the use of conventional TACE (8-11).
Embolic Agents
Commonly used embolic agents include gelatin sponges,
polyvinyl alcohol (PVA) particles and microspheres. The
use of steel coils, autologous blood clots and degradable
starch microspheres as embolic agents has also been
reported. Among these, PVA, microspheres and steel coils
are considered permanent embolic agents while the other
agents only embolize temporarily. Each of these agents can
be prepared in various sizes and each agent has different
characteristics; therefore, it is difficult to determine which
embolic agent is the most appropriate especially as each
tumor has a different size and vascularity. In general, the
use of agents that can embolize as much as possible the
peripheral portions of the hepatic artery for the effective
interruption of hepatic arterial flow would be favored as
the agents can prevent the development of collateral
arterial flow to a tumor. However, it has been found that
embolic agents such as gelatin powder that are able to
reach far smaller vessels can damage extratumoral liver
tissue. This damage results in biliary strictures and bile duct
cysts, and such agents are no longer used for TACE (12-
14). A gelatin sponge is the most widely used embolic
agent that can be prepared in various forms such as
particles, pellets or fragments, and the use of a gelatin
sponge results in temporary occlusion of an artery with
recanalization taking place within two weeks (15, 16).
Hepatic artery embolization done with a gelatin sponge
alone has been shown to cause no damage to the liver in
an experimental study (17).
A novel system combining PVA beads and doxorubicin
as drug-eluting beads (DEB) is supposed to release doxoru-
bicin in a slow and controlled manner. A recent study of
TACE using DEB has shown that DEB could further
improve the pharmacokinetics of the injected doxorubicin
and reduce drug-related side effects maintaining the same
therapeutic efficacy as TACE (18). The clinical benefits of
DEB need to be confirmed with randomized controlled
studies (RCTs) that compare the use of DEB to TACE.
Lipiodol
Lipiodol (iodized oil; Guerbet Laboratories, Roissy,
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Fig. 1. 66-year-old man with hepatocellular carcinoma.
E, F. One year later, follow-up CT scan shows shrunken tumors without any evidence of viable tumor. Size of tumor thrombus in inferior
vena cava has markedly decreased as well (arrow in F). Initial serum level of α FP was 917.0 ng/ml and it returned to normal (2.6 ng/ml).
EFFrance), an iodinated ethyl ester of poppy seed oil, is an
oily contrast medium and has been used for lymphangio-
graphic studies. Though TAE has been used to treat HCC
since it was first reported in 1974 (19), the use of TACE to
treat HCC really began after Lipiodol was introduced as a
drug carrier and an embolic agent in the early 1980s (20).
When injected into the hepatic artery, Lipiodol selectively
remains more in tumor nodules for several weeks to over a
year due to a siphoning effect from hypervascularization of
the tumor vessels and an absence of Kupffer cells inside
tumor tissues (21, 22). This results in the embolic effects on
smaller vessels. However, Lipiodol injected into the
hepatic artery of normal liver parenchyma accumulates in
the portal venules by arterioportal communication and is
gradually released into the systemic circulation via the
hepatic sinusoids or undergoes phagocytosis by Kupffer
cells and is usually cleared within a week (17, 21, 23).
Lipiodol has another role as a vehicle to carry and localize
chemotherapeutic agents inside a tumor. Anticancer drugs
used in conjunction with Lipiodol include doxorubicin,
epirubicin, aclarubicin, 5-fluorouracil, mitomycin, cisplatin
and SMANCS (styrene maleic acid neocarzinostatin). The
anticancer drugs are vigorously mixed with the Lipiodol
through the use of a pumping method to prepare an
emulsion, and when the emulsified Lipiodol and drug
mixture is injected into a tumor supplying vessels, the
anticancer drug is slowly released from Lipiodol and
remains in high concentrations within the tumor for a
prolonged period (24).
There have been concerns that such emulsions may not
be stable and anticancer drugs are released too quickly into
the systemic circulation. In a study done by Johnson et al.
(25), there was no difference with regard to pharmacoki-
netic parameters or toxicity of intraarterial administration
of doxorubicin with or without Lipiodol compared to
intravenous doxorubicin. However, this study appears
technically flawed as the volume of normal saline (25 ml)
used to dissolve doxorubicin was excessive compared to
the volume of Lipiodol (10 ml). How to make a stable
emulsion with water-based preparations for anticancer
drugs and oil (Lipiodol) has been a major issue as the
stability of the mixture can greatly influence the pharma-
cokinetic characteristics of the anticancer drugs; hence, the
clinical benefits of TACE. Studies have found that the
stability of the emulsion is greatly influenced by the
volume ratio between Lipiodol and the contrast medium
used to dissolve the anticancer agents, and the highest
stability for Lipiodol and contrast medium was obtained at
a ratio of 2-4:1 (26, 27). An experimental study
demonstrated that an excess volume of Lipiodol over
contrast medium results in water-in-oil emulsions with
increased tumor uptake of Lipiodol while minimizing non-
tumor or lung uptake of Lipiodol compared to an oil-in-
water type emulsion (28). A clinical study by Nakamura et
al. (24) has shown that doxorubicin was released slowly
from a water-in-oil emulsion resulting clearly in a lower
blood doxorubicin concentration compared to intraarterial
injection of the drug without Lipiodol. From the results of
these studies, it is assumed that improved pharmacokinetic
outcomes of TACE can be obtained by adjusting the
mixing volume of Lipiodol and doxorubicin to a 2-3:1
ratio (Lipiodol/doxorubicin solution) (24). Another study
that used a water-in-oil emulsion investigated the effect of
concurrent use of gelfoam and found that the pharmacoki-
netic ameliorations were even more pronounced after
gelfoam embolization. It was concluded that from a kinetic
standpoint, the use of a doxorubicin-Lipiodol-gelfoam
combination provided the best effect (29). This study
implied that gelfoam embolization functions to release
doxorubicin more slowly from Lipiodol, hence further
increasing the drug concentration inside the tumor by
preventing washout of the emulsion as well as increasing
the embolization effect. The stability of the emulsion could
even be more enhanced by adjusting the specific gravity of
the contrast medium by adding a small amount of distilled
water so it is close to the specific gravity of Lipiodol (24,
27).
Another advantage of using Lipiodol is that Lipiodol can
reach the portal veins around tumors because of arterio-
portal communication through the peribiliary vascular
plexus, the vasa vasorum of the portal vein and drainage
routes from a tumor itself (17, 30). While encapsulated
nodular HCCs receive its blood supply almost exclusively
from the hepatic artery, the periphery of HCC nodules or
advanced HCCs with extracapsular invasion or early
HCCs have a dual blood supply both from the hepatic
artery and the portal vein leading to resistance to TACE
and incomplete tumor necrosis after TACE (31, 32). The
deposition of Lipiodol in the portal veins around a tumor
has been reported to strengthen anti-tumor effects and
conventional embolizations without Lipiodol did not
produce such strengthen antitumor effects (33). Local
tumor recurrence was significantly lower when a greater
degree of portal vein visualization with Lipiodol was
demonstrated during TACE (10) (Fig. 2).
In summary, Lipiodol has several functions. Lipiodol
functions as a microvessel embolic agent, as a carrier of
chemotherapeutic agents and as an augmenter of antitu-
mor effects of TACE by efflux into the portal veins.
Though the use of Lipiodol in TACE has been challenged
(4), there is substantial evidence that confirms the efficacy
of the use of Lipiodol. Lipiodol is still widely adopted in
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Chemotherapeutic Agents
Chemotherapeutic agents are usually suspended in
iodized oil and are delivered as close to a tumor as possible
followed by the embolization process. Several chemother-
apeutic agents have been used with doxorubicin and
cisplatin being the most common. The usual dose for
doxorubicin and cisplatin per session is 10-70 mg and 10-
120 mg respectively (4, 34). The criteria to determine the
dosages of chemotherapeutic agents are variable and not
standardized: some authors refer to patient’s body surface
area, weight, tumor burden or bilirubin level, and some
used a fixed dose. A few RCTs have failed to show signifi-
cant differences in survival between the use of doxorubicin
and other drugs such as cisplatin or epirubicin (35-37), and
to date, there is no evidence of the superiority of any
single chemotherapeutic agent over other drugs or for
mono-drug chemotherapy versus combination chemother-
apy (4).
Therapeutic Efficacy of Transarterial
Chemoembolization
Transarterial chemoembolization can induce extensive
Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment
Korean J Radiol 10(5), Sep/Oct 2009 429
AB
Fig. 2. 56-year-old man with hepatocellular carcinoma.
A, B. Contrast enhanced CT scans show two enhancing nodules (arrowheads) in liver segment 7 (A) and segment 8 (B). Serum α FP
level was 5826.7 ng/ml.
C. Hepatic arteriogram shows two hypervascular tumor nodules (arrows) in corresponding segments. Segmental transarterial chemoem-
bolization was performed with mixture of 5 ml of Lipiodol and 20 mg of doxorubicin followed by gelfoam embolization.
D. Post-transarterial chemoembolization plain radiograph shows better deposition of Lipiodol in portal vein around tumor in segment 7
(arrows) when compared to tumor in segment 8 (arrowheads).
CDtumor necrosis in most patients and this has been substanti-
ated by the pathological identification of tumor necrosis,
by a reduction in tumor burden as seen on contrast
enhanced CT scans and by a decrease in tumor marker
concentrations after the procedure (9, 38). The objective
response rate of TACE has been reported between 15%
and 61% (39-45) and TACE appeared to prevent signifi-
cant tumor progression compared with conservative or
inactive treatments (39, 40). 
However, the ability of TACE to induce tumor necrosis
does not necessarily mean longer survival rates for HCC
patients. Almost 70-80% of patients treated with TACE
die due to tumor progression during follow-up because of
the eventual regrowth of the residual tumor cells after
regaining a vascular supply or the remote recurrence of
tumors in other areas of the liver. The most reliable way to
confirm a survival benefit is through the use of large RCTs
that compare treatment versus no treatment; however,
small RCTs have failed to show a survival advantage of
TACE (39, 40, 42-44) and until recently, the use of TACE
was controversial in HCC patients not indicated for
curative therapies.
In 2002, two RCTs from Hong Kong (45) and Spain (41)
showed the survival benefits of TACE compared to the
best conservative treatment. Llovet et al. (41) compared
TACE to the use of gelatin sponges and doxorubicin
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Fig. 2. 56-year-old man with hepatocellular carcinoma.
E. Follow-up CT scan one month later shows residual tumor enhancement in segment 8 (arrowheads). In contrast, CT reveals compact
Lipiodol retention in tumor of segment 7 without evidence of viable tumor (not shown). Serum α FP level was 177.9 ng/ml.
F. Hepatic arteriogram for second session transarterial chemoembolization shows tumor staining in segment 8 (arrows) in agreement
with CT findings. No tumor staining is noted in segment 7 tumor.
G. After subsegmental transarterial chemoembolization, Lipiodol deposition appears better in portal vein around segment 8 tumor
(arrows) when compared with that of previous transarterial chemoembolization. 
H. Four months after second transarterial chemoembolization, follow-up CT scan shows compact Lipiodol uptake in both of tumors
without any viable tumor portion. Serum α FP level returned to normal (2.9 ng/ml).
GHdissolved in Lipiodol and TAE to the use of gelatin sponges
and conservative treatment. An interim analysis showed
that TACE had survival benefits compared to the conserv-
ative treatment (hazard ratio of death, 0.47; 95%
confidence interval, 0.25-0.91), and the survival probabili-
ties at one and two years were 82% and 63% for TACE,
75% and 50% for TAE and 63% and 27% for conserva-
tive treatment, respectively (TACE versus conservative
treatment, p = 0.009). In addition, treatment allocation was
the only variable independently related to survival.
Another RCT from Hong Kong compared the use of TACE
to an emulsion of cisplatin in Lipiodol and gelatin sponges
and symptomatic treatment (45). The study showed that
survival was better in patients treated with TACE (1-year
survival, 57%; 2-year survival, 31%; 3-year survival,
26%) than in patients that received symptomatic treatment
(1-year survival, 32%; 2-year survival, 11%; 3-year
survival, 3%; p = 0.002).
These RCTs were followed by cumulative meta-analyses
which included all published RCTs (46, 47) showing that
TACE significantly reduced the overall 2-year mortality
rate compared to control patients who received conserva-
tive or inactive treatments (odds ratios, 0.53 and 0.54;
95% confidence interval, 0.32-0.89 and 0.33-0.89; 
p = 0.015 and 0.017, respectively). However, two RCTs
presented contrary results for a comparison between
TACE and TAE and one study failed to show any evidence
that TACE was more effective than TAE (46). The results
of RCTs that have compared the use of TACE or TAE
versus inactive treatments are summarized in Table 1.
In one prospective study that compared the use of TACE
and hepatic resection (48), there was no significant survival
difference between TACE and hepatic resection for
advanced HCCs (UICC [Union Internationale Contre Le
Cancer] stage T3 N0 M0), and even in patients with UICC
stage T1-2 N0 M0 HCC when Lipiodol was compactly
retained, the survival rate after TACE was comparable to
the survival rate after hepatic resection. The extent of
Lipiodol retention translates into response to treatment.
Complications
Transarterial chemoembolization can cause a variety of
complications. However, the procedural complications
usually arise from underlying causative factors or an
application of inadvertent techniques. The causative
factors include compromised liver function, main portal
vein obstruction, biliary tract obstruction, a previous
history of bile duct surgery, Lipiodol overdosage, hepatic
artery occlusion due to repeated TACE and nonselective
TACE (49). Therefore, the presence of any of these factors
should be identified prior to performing TACE and an
adjustment of the dosage for the drug and the application
of a meticulous technique must be implemented accord-
Transarterial Chemoembolization for Hepatocellular Carcinoma Treatment
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Table 1. Response and Survival Rates of HCC Patients in Randomized Controlled Trials Comparing TACE/TAE versus Inactive
Treatments
Author Journal, Year
Treatment Arms  Objective  Survival (%)
Risk Factors for Survival
(No. of Patients) Response (%) 1-year 2-year
Lin et al. (42) Gastroenterology,  TAE (21) 62 42 25 NR
1988 TAE + IV 5-FU (21) 48 20 20
IV 5-FU (21) 9.5 13 13
Pelletier et al. (43) J Hepatol, 1990 TACE (21) 33 24 NR NR
Control (21) 0 33 NR
GETCH (40) N Engl J Med, 1995 TACE (50) 16 62 38 Performance, liver function,
tumor mass, PVT, α FP
Control (46) 5 43 26
Bruix et al. (39) Hepatology, 1998 TAE + coils (40) 55 70 49 Performance, bilirubin
Control (40) 0 72 50
Pelletier et al. (44) J Hepatol, 1998 TACE + tamoxifen (37) 24 51 24 Child-Pugh class
Tamoxifen (36) 5.5 55 26
Lo et al. (45) Hepatology, 2002 TACE (40) 27 57 31 TACE, PVT
Control (39) 2.6 32 11
Llovet et al. (41) Lancet, 2002 TAE (37) 43 75 50 TACE, symptom
TACE (40) 35 82 63
Control (35) 0 63 27
Note.─ HCC = hepatocellular carcinoma, TACE = transarterial chemoembolization, TAE = transarterial embolization, IV = intravenous, NR = not reported, 
5-FU = 5-fluorouracil, PVT = portal vein tumor thrombosis, α FP = alpha-fetoproteiningly.
The most common complication of TACE is post-
embolization syndrome that consists of transient abdomi-
nal pain and fever occurring in 60-80% of the patients
after TACE. Elevation of the level of hepatic transaminases
typically accompanies post-embolization syndrome (50).
Whether post-embolization syndrome reflects damage to
the normal liver parenchyma or tumor necrosis is
uncertain. Though prolonged hospitalization may be
required to monitor a patient and to control pain, post-
embolization syndrome is self-limiting within 3-4 days,
and the use of antibiotics is not necessary to treat the fever
(51).
Hepatic failure after TACE is related to TACE-induced
ischemic damage to the non-tumorous liver tissue and
several risk factors have been identified including portal
vein obstruction, the use of a high dose of anti-cancer
drugs and Lipiodol, a high basal level of bilirubin, a
prolonged prothrombin time and advanced Child-Pugh
class (49, 52). Because the definitions of TACE-induced
hepatic failure are different in each study, the reported
incidence of hepatic failure has varied widely from 0-49%,
with a median incidence of 8% (4). Though deterioration
of liver function recovers to the pretreatment level before
the next session of TACE in most patients and only 3% of
patients had irreversible hepatic decompensation (4),
TACE should be performed with extreme caution in
patients having risk factors for hepatic failure.
Other TACE-related complications occur in less than
10% of treatment sessions and include ischemic cholecysti-
tis, hepatic abscesses and biliary strictures (34).
Cholecystitis or gallbladder infarction frequently occurred
after inadvertent injection of the Lipiodol mixture or
embolization of the cystic artery; however, most cases are
asymptomatic and rarely require intervention with
percutaneous drainage or a cholecystectomy (53, 54). Song
et al. (55) reviewed the risk of liver abscesses in 6,255
TACE procedures and found a 0.2% incidence rate of liver
abscesses. Development of a liver abscess has been linked
to previous intervention in the biliary system being prone
to an ascending biliary infection (55). The prophylactic use
of antibiotics and a bowel enema could be considered in
these patients.
Bile duct injury including a subcapsular biloma, focal
strictures of the common hepatic or bile duct and diffuse
dilatation of the intrahepatic ducts has been reported with
a 0.5-2% incidence (56, 57). Bilomas seem to be associ-
ated with the use of Lipiodol and focal strictures of large
bile ducts with the use of gelatin sponge particles (56).
Therefore, careful use of these agents with a meticulous
level of embolization may reduce bile duct injury.
Upper gastrointestinal complications such as gastritis,
ulceration and bleeding can occur after TACE caused by
the regurgitation of embolic agents into the gastric arteries,
by the presence of anatomic variants (e.g., an accessory left
gastric artery arising from the left hepatic artery) and by
the development of stress ulcers. Upper gastrointestinal
bleeding occurred in 3% (median) of the patients (range,
0-22%) in 23 trials that involved 2,593 patients (4). It is
essential to recognize the presence of any of the anatomic
variants and to prevent the efflux of a drug into the
gastrointestinal organs.
Conclusion and Future Perspectives
It has been shown that TACE is the only palliative
treatment that can benefit HCC patients ineligible for
curative treatment in terms of survival, and TACE has
been widely accepted as standard therapy in selected
patients. However, several important issues remain to be
clarified including what is the best chemotherapeutic drug
to employ, what is the best embolization agent to utilize
and what is the most appropriate retreatment schedule.
Most importantly, the survival gain of TACE seems to be
marginal, partly due to HCCs having tumor portions
supplied by the portal vein such as the periphery or the
extracapsular portion of an advanced HCC though the use
of Lipiodol has a theoretical advantage as it can reach the
portal vein (31, 32). Recent advancement in microcatheter
technology has made it possible to perform ultraselective
catheterization of tumor feeding arteries. Miyayama et al.
(10) used a newly designed 2-Fr tip microcatheter to facili-
tate superselective catheterization of tumor feeders and
the overflow of Lipiodol emulsion into the portal vein.
With the use of this technique, marked visualization of the
portal veins due to overflowed Lipiodol emulsion was
noted in almost half of the tumors and a greater grade of
portal vein visualization was associated with lower local
tumor recurrence. Another strategy to improve the
therapeutic effect of TACE may be the use of DEB (18).
DEB consists of PVA beads and doxorubicin, and PVA
beads loaded with doxorubicin is supposed to act as a drug
carrier capable of releasing doxorubicin in a slow and
controlled manner. In a recent study, the pharmacokinetic
profiles of injected doxorubicin were significantly better in
TACE using DEB than in conventional TACE and the
reported 1-year and 2-year survival after TACE using DEB
was 93% and 89%, respectively (18). There have been
efforts to improve therapeutic efficacy of TACE by
combining TACE with other modality treatments such as
radiofrequency ablation (RFA). Cheng et al. (58) recently
showed that the use of combined TACE-RFA was superior
Shin
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reporting that the median survival time of the patients
treated with TACE-RFA was 37 months while median
survival times of TACE alone and RFA alone were 24
months and 22 months, respectively. Through these
investigations, the limitations of TACE are expected to be
overcome, and it is hoped to expand the indications and
clinical benefits of TACE.
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